29 May 2016

Hydrodec hails transformer deal

24/08/06 Robert Tyerman

Profitability is now in sight claims 'green' oil technology hopeful Hydrodec following a bulk order for its 'Superfine' transformer oil.

AIM-quoted Hydrodec, set up to commercialise Australian technology to remove harmful contaminants in oil refining, says written acceptance from a major transformer manufacturer Down Under and conditional acceptance from another for bulk use of Superfine could ensure a firm market for at least half the capacity of Hydrodec's newly-commissioned refining plant in New South Wales. That, says the company, should generate annual revenues of £1.8 million, underpinned by feedstock supply commitments from major utilities.

John Gunn, the former City tycoon-turned young company backer who chairs Hydrodec, says the company, which lost nearly £6 million last year, will now be 'cash-flow positive next month and profitable in the fourth quarter'. The New South Wales plant is 'on time, and under budget' and should reach 80 per cent capacity by the end of the year and hit its full 20,000-litres-a-day potential by the first quarter of 2007.

He says the contracts 'go on', without a set termination date, and argues that Superfine faces a 'virtuous circle'. It is 'very "green" and self-sustaining': once used or filtered, it can be re-used and re-refined and 'we will refresh it and give it back over the long term.

'We have done the tests', explains Gunn, 'and the product comes up better than new after this process, with even less sulphur second time round'. With a management team boasting senior experience at chemical giants Dow , Du Pont and ICI, he says Hydrodec now intends to build a new plant and is weighing whether to site it in the USA, Japan, Turkey or Germany.

Gunn insists Hydrodec, which ended last year with £3.3 million cash and put a value of £7.3 million on its patented technology, is not looking for joint venture partners. 'We will need no new money until we have to build the new plant', he asserts.

At 28.75p, Hydrodec is a long-term gamble, which could pay off handsomely if present hopes are realised.

Growth Company Investor’s award-winning team offer outstanding share recommendation performance. Get immediate access to all these recommendations – click here.

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Motif Bio and the ticking timebomb 23/05/16

The recently published O'Neill report on antimicrobial resistance shows it to be a ticking timebomb. Resistance to antibiotics raises the prospect of 10 million deaths a year by 2050. This is a big opportunity for AIM listed Motif Bio (AIM: MTFB).      

Make mine a double! 19/05/16

Fevertree Drinks (AIM: FEVR) has been one of the most spectacular new issues on AIM in recent years, rising 412 per cent from the float price in late 2014. Today’s trading update served to emphasise why the shares are doing so well and drove them up another 15 per cent.

Fox Marble might be worth the wait  16/05/16

Fox Marble (AIM: FOX) has raised £2 million through a placing at 10p. The funds will be mainly used to complete its long-delayed marble processing factory in Kosovo. Fox has an exciting story but unfortunately is lagging way behind its original roadmap to profitability.

Business as usual at XL Media  12/05/16

XL Media (AIM: XLM) has announced the result of its strategic review. I hope no one was holding their breath, because the conclusion is to carry on as usual! The good news is that trading is said to have ‘maintained its excellent start to 2016’.

A Quantum of solace 11/05/16

Quantum Pharma (AIM: QP.) committed the cardinal sin of overpromising and under-delivering during its first year on AIM. New products took longer to come through the regulatory process than expected, which caused downgrades and a share price collapse from a high of 172p last June to the current 58p. However results for the financial year which ended in January suggest the company is getting to grips with the problems in its Niche Pharmaceuticals division.

Elecosoft constructs a strategy for growth  09/05/16

Elecosoft (AIM: ELCO) is a specialist software company serving architects and builders. It used to be a much larger business but sold out of its building materials businesses four years ago to focus on its software arm. The challenge now is to generate some revenue growth and move off a sales plateau which has been in place since then.

More News